471 related articles for article (PubMed ID: 33127856)
1. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme.
Cohen SB; Tanaka Y; Mariette X; Curtis JR; Lee EB; Nash P; Winthrop KL; Charles-Schoeman C; Wang L; Chen C; Kwok K; Biswas P; Shapiro A; Madsen A; Wollenhaupt J
RMD Open; 2020 Oct; 6(3):. PubMed ID: 33127856
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.
Cohen SB; Tanaka Y; Mariette X; Curtis JR; Lee EB; Nash P; Winthrop KL; Charles-Schoeman C; Thirunavukkarasu K; DeMasi R; Geier J; Kwok K; Wang L; Riese R; Wollenhaupt J
Ann Rheum Dis; 2017 Jul; 76(7):1253-1262. PubMed ID: 28143815
[TBL] [Abstract][Full Text] [Related]
3. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial.
Curtis JR; Yamaoka K; Chen YH; Bhatt DL; Gunay LM; Sugiyama N; Connell CA; Wang C; Wu J; Menon S; Vranic I; Gómez-Reino JJ
Ann Rheum Dis; 2023 Mar; 82(3):331-343. PubMed ID: 36600185
[TBL] [Abstract][Full Text] [Related]
4. Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs.
Winthrop KL; Yndestad A; Henrohn D; Danese S; Marsal S; Galindo M; Woolcott JC; Jo H; Kwok K; Shapiro AB; Jones TV; Diehl A; Su C; Panés J; Cohen SB
Rheumatol Ther; 2023 Apr; 10(2):357-373. PubMed ID: 36526796
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials.
Panaccione R; Isaacs JD; Chen LA; Wang W; Marren A; Kwok K; Wang L; Chan G; Su C
Dig Dis Sci; 2021 Aug; 66(8):2732-2743. PubMed ID: 32816215
[TBL] [Abstract][Full Text] [Related]
6. Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment.
Winthrop KL; Curtis JR; Yamaoka K; Lee EB; Hirose T; Rivas JL; Kwok K; Burmester GR
Rheumatol Ther; 2022 Feb; 9(1):243-263. PubMed ID: 34870800
[TBL] [Abstract][Full Text] [Related]
7. Fracture in clinical studies of tofacitinib in rheumatoid arthritis.
Hansen KE; Mortezavi M; Nagy E; Wang C; Connell CA; Radi Z; Litman HJ; Adami G; Rossini M
Ther Adv Musculoskelet Dis; 2022; 14():1759720X221142346. PubMed ID: 36601090
[TBL] [Abstract][Full Text] [Related]
8. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance.
Kristensen LE; Danese S; Yndestad A; Wang C; Nagy E; Modesto I; Rivas J; Benda B
Ann Rheum Dis; 2023 Jul; 82(7):901-910. PubMed ID: 36931693
[TBL] [Abstract][Full Text] [Related]
9. Risk Stratification of Patients with Psoriatic Arthritis and Ankylosing Spondylitis for Treatment with Tofacitinib: A Review of Current Clinical Data.
Kristensen LE; Deodhar A; Leung YY; Vranic I; Mortezavi M; Fallon L; Yndestad A; Kinch CD; Gladman DD
Rheumatol Ther; 2024 Jun; 11(3):487-499. PubMed ID: 38696034
[TBL] [Abstract][Full Text] [Related]
10. A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population.
Kivitz AJ; Cohen S; Keystone E; van Vollenhoven RF; Haraoui B; Kaine J; Fan H; Connell CA; Bananis E; Takiya L; Fleischmann R
Semin Arthritis Rheum; 2018 Dec; 48(3):406-415. PubMed ID: 30177460
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs.
Charles-Schoeman C; Burmester G; Nash P; Zerbini CA; Soma K; Kwok K; Hendrikx T; Bananis E; Fleischmann R
Ann Rheum Dis; 2016 Jul; 75(7):1293-301. PubMed ID: 26275429
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study.
Wollenhaupt J; Lee EB; Curtis JR; Silverfield J; Terry K; Soma K; Mojcik C; DeMasi R; Strengholt S; Kwok K; Lazariciu I; Wang L; Cohen S
Arthritis Res Ther; 2019 Apr; 21(1):89. PubMed ID: 30953540
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of tofacitinib in patients with rheumatoid arthritis by previous treatment: post hoc analysis of phase II/III trials.
Tesser J; Gül A; Olech E; Oelke K; Lukic T; Kwok K; Ebrahim A
Arthritis Res Ther; 2023 Nov; 25(1):214. PubMed ID: 37919780
[TBL] [Abstract][Full Text] [Related]
14. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
Mease P; Charles-Schoeman C; Cohen S; Fallon L; Woolcott J; Yun H; Kremer J; Greenberg J; Malley W; Onofrei A; Kanik KS; Graham D; Wang C; Connell C; Valdez H; Hauben M; Hung E; Madsen A; Jones TV; Curtis JR
Ann Rheum Dis; 2020 Nov; 79(11):1400-1413. PubMed ID: 32759265
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data.
Lee EB; Yamanaka H; Liu Y; Tsai WC; Chen C; Kwok K; Yoo HJ; Llamado LJ; Wang L; Luo Y; Sugiyama N; Tanaka Y
Int J Rheum Dis; 2019 Jun; 22(6):1094-1106. PubMed ID: 30900375
[TBL] [Abstract][Full Text] [Related]
16. Safety of Tofacitinib in the Treatment of Rheumatoid Arthritis in Latin America Compared With the Rest of the World Population.
Castañeda OM; Romero FJ; Salinas A; Citera G; Mysler E; Rillo O; Radominski SC; Cardiel MH; Jaller JJ; Alvarez-Moreno C; Ponce de Leon D; Castelli G; García EG; Kwok K; Rojo R
J Clin Rheumatol; 2017 Jun; 23(4):193-199. PubMed ID: 28145906
[TBL] [Abstract][Full Text] [Related]
17. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.
Curtis JR; Lee EB; Kaplan IV; Kwok K; Geier J; Benda B; Soma K; Wang L; Riese R
Ann Rheum Dis; 2016 May; 75(5):831-41. PubMed ID: 25902789
[TBL] [Abstract][Full Text] [Related]
18. Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinib.
Curtis JR; Zhang R; Krishnaswami S; Anisfeld A; Chen Y; Strengholt S; Chen C; Geier J
Clin Rheumatol; 2017 Mar; 36(3):683-688. PubMed ID: 27470086
[TBL] [Abstract][Full Text] [Related]
19. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.
Radominski SC; Cardiel MH; Citera G; Goecke A; Jaller JJ; Lomonte ABV; Miranda P; Velez P; Xibillé D; Kwok K; Rojo R; García EG
Reumatol Clin; 2017; 13(4):201-209. PubMed ID: 27317492
[TBL] [Abstract][Full Text] [Related]
20. Tofacitinib in the treatment of Indian patients with rheumatoid arthritis: A post hoc analysis of efficacy and safety in Phase 3 and long-term extension studies over 7 years.
Chopra A; Shobha V; Chandrashekara S; Veeravalli SCM; Sharma R; Rao UR; Pandya S; Wagh S; Kadel JK; Thorat AV; Adhav C; Santos Estrella P; Yu W; Kwok K; Wouters A
Int J Rheum Dis; 2020 Jul; 23(7):882-897. PubMed ID: 32478474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
